Nomora Limited
Registered name: NOMORA LIMITED
Nomora Limited made £0 revenue and a £6.5k loss in the year to 31 Dec 2025. read from filing text
Nomora Limited’s revenue was £0 in the year to 31 Dec 2025, with a loss of £6.5k and 0 employees. The company is classified under “research and experimental development on biotechnology” and is based in London; we hold 4 years of its filed accounts.
- Status
- Active
- Location
- London, London
- Age
- 4 yrs · since 2021
- Type
- Private Limited Company
Key figures
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 31 Dec 2022 | 31 Dec 2023 | 31 Dec 2024 | 31 Dec 2025 |
|---|---|---|---|---|
| Disclosure | No P&L | No P&L | Full P&Lread from filing text | Full P&Lread from filing text |
| Profit & loss | ||||
| Revenue (turnover) | — | — | £0 | £0 |
| Cost of sales | — | — | £0 | £0 |
| Gross profit | — | — | £0 | £0 |
| Operating profit | — | — | −£12k | −£6.5k |
| Profit before tax | — | — | −£12k | −£6.5k |
| Profit after tax | — | — | −£12k | −£6.5k |
| Profit (best available) | — | — | −£12k | −£6.5k |
| Employees (average) | 0 | 0 | 0 | 0 |
| Ratios | ||||
| Profit margin | — | — | — | — |
| Balance sheet — indirect signals, not revenue | ||||
| Cash at bank | £2.4k | £3.9k | £528 | £2k |
| Net assets | £965 | −£2.5k | −£14.5k | −£21k |
| Current assets | £2.6k | £4.1k | £576 | £2k |
| Debtors | £225 | £173 | £48 | £31 |
| Source | FullAccounts · bulk data May 2024 | FullAccounts · bulk data May 2024 | FilletedAccounts · bulk data Feb 2025 | FilletedAccounts · bulk data Jun 2026 |
How the business works
- Profit margin
- —
- Profit ÷ revenue.
- Gross margin
- —
- Gross profit ÷ revenue. High for software and services.
- Revenue per employee
- —
- Revenue ÷ average employees.
- Profit per employee
- —
- Profit ÷ average employees.
- Cash conversion
- —
- Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
- Fixed assets ÷ revenue
- —
- Capital intensity. Low = capital-light, cheaper to start.
- Deferred income ÷ revenue
- —
- Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
- Debtors ÷ revenue
- —
- Money owed by customers. Low = customers pay quickly.
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- —
- Now −£21k
- Cash at bank
- ▲281%
- Now £2k
- Headcount
- —
- Now 0
- Deferred income
- —
- Now —
- Fixed assets
- —
- Now —
Similar profitable businesses
- Astex Therapeutics LimitedCambridge · Research and experimental development on biotechnology
- Revenue
- £404m
- Profit
- £283m
- Staff
- 183
- Amphista Therapeutics LimitedCambridge · Research and experimental development on biotechnology
- Revenue
- £33.9m
- Profit
- £19.8m
- Staff
- 56
- Charles River U.K. LimitedKent · Research and experimental development on biotechnology
- Revenue
- £22.2m
- Profit
- £18.8m
- Staff
- 129
- Qiagen Manchester LimitedManchester · Research and experimental development on biotechnology
- Revenue
- £53.7m
- Profit
- £11.8m
- Staff
- 239
- Alchemab Therapeutics LtdLondon · Research and experimental development on biotechnology
- Revenue
- £30m
- Profit
- £8.3m
- Staff
- 55
- Ligand UK Development LimitedLondon · Research and experimental development on biotechnology
- Revenue
- £8.7m
- Profit
- £6m
- Staff
- —
Sources
Latest figures from FilletedAccounts for the year to 31 Dec 2025 (profit −£6.5k), from the Companies House accounts bulk data published Jun 2026. Spotted an error? Request a correction.
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.